Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1791343 | 1.00 | — | — | |
| Acetic Acid SCHEMBL4600958 | 0.96 | FFAR3 (0.50) | FFAR3LCKFYNLMNATDP1 | |
| Acetic Acid SCHEMBL3244968 | 0.96 | FFAR3 (0.50) | FFAR3LCKFYNLMNATDP1 | |
| Acetic Acid SCHEMBL28151662 | 0.96 | FFAR3 (0.50) | FFAR3LCKFYNLMNATDP1 | |
| Acetic Acid SCHEMBL15658788 | 0.96 | FFAR3 (0.58) | FFAR3LCKFYNLMNATDP1 | |
| Acetic Acid SCHEMBL4986972 | 0.96 | FFAR3 (0.58) | FFAR3LCKFYNLMNATDP1 | |
| Acetic Acid SCHEMBL211103 | 0.96 | — | — | |
| Acetic Acid SCHEMBL11256435 | 0.96 | FFAR3 (0.58) | FFAR3LCKFYNLMNATDP1 | |
| Acetic Acid SCHEMBL16004804 | 0.96 | FFAR3 (0.58) | FFAR3LCKFYNLMNATDP1 | |
| Acetic Acid SCHEMBL15657988 | 0.96 | FFAR3 (0.58) | FFAR3LCKFYNLMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111606815-B | Preparation method of phenylephrine hydrochloride impurity standard | 珠海安哲生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-111606815-A | Preparation method of phenylephrine hydrochloride impurity standard | 珠海安哲生物科技有限公司 | 2020-09-01 | — | — | CN | claimed |
| CN-101703583-B | Quality detection method of Xinning capsules | GUIYANG XIN TIAN PHARMACEUTICAL CO LTD | 2012-05-30 | — | — | CN | claimed |
| CN-101703583-A | Method for detecting quality of Xinning capsule | GUIYANG XIN TIAN PHARMACEUTICA | 2010-05-12 | — | — | CN | claimed |
| CN-117214336-A | Method for detecting epipiprazole, intermediate and impurity | 湖南省湘中制药有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-116256438-A | Analysis and detection method for beraprost sodium intermediate III isomer | 重庆药友制药有限责任公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11534494-B2 | Formulation and method of synthesis | GE HEALTHCARE LIMITED (GB) | 2022-12-27 | — | — | US | disclosed |
| US-11297863-B2 | Emulsified seasoning | KAO CORPORATION (JP) | 2022-04-12 | — | — | US | disclosed |
| WO-2022034226-A1 | AVERMECTIN AND MILBEMYCIN COMPOSITIONS FOR INHALATION | UNIVERSIDAD DE NAVARRA (ES) | 2022-02-17 | — | — | WO | disclosed |
| CN-111606815-B | Preparation method of phenylephrine hydrochloride impurity standard | 珠海安哲生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20220001034-A1 | NOVEL FORMULATION AND METHOD OF SYNTHESIS | GE HEALTHCARE LTD (GB) | 2022-01-06 | — | — | US | disclosed |
| US-11206858-B2 | Separated liquid seasoning | KAO CORPORATION (JP) | 2021-12-28 | — | — | US | disclosed |
| US-20090023596-A1 | In Vitro Model Of Latent Mycobacterial Infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-22 | — | — | US | disclosed |
| WO-2008134298-A1 | IN VITRO MODEL OF LATENT MYCOBACTERIAL INFECTION | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080248155-A1 | Use of Stevensite For Mycotoxin Adsorption | SUD-CHEMIE AG (DE) | 2008-10-09 | — | — | US | disclosed |
| CN-101241114-A | Animal source food sulfonamide residual medium solid phase dispersion-highly effective liquid phase chromatography determination method | BEIJING GLORIOUS LAND AGRICULT (CN) | 2008-08-13 | — | — | CN | disclosed |
| US-6613539-B1 | Use as a mass screening technique to measure the biological activity of large quantities of compounds using an orthogonal array method | WARNER LAMBERT COMPANY | 2003-09-02 | — | — | US | disclosed |
| US-6204034-B1 | ENZYME WITH DEFINED PARTIAL AMINO-TERMINAL AMINO ACID SEQUENCE; ENZYME INHIBITORS; ANTIBODIES; ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2001-03-20 | — | — | US | disclosed |
| WO-1993025668-A1 | LEUKOTRIENE C4 SYNTHASE | MERCK FROSST CANADA INC. (CA) | 1993-12-23 | — | — | WO | disclosed |
| US-4835707-A | Automatic analysis method and apparatus for enzyme reaction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534494-B2 | Formulation and method of synthesis | PFAS, ARF5, FAU | FFAR3 341/4885LCK 3026/4885FYN 1379/4885 |
| US-20220001034-A1 | NOVEL FORMULATION AND METHOD OF SYNTHESIS | AFF1, PAICS, FOLR1 | FFAR3 25/4885LCK 4078/4885FYN 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.